drugset / Trial / NCT01876368
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan
Timeline
- Start
- 2013-09
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCZ696 | Unknown | 200 mg | — |
| Comparator | Olmesartan | Other / unclassified | 20 mg | — |